Bumadizone calcium in the treatment of rheumatoid arthritis.
A double-blind crossover trial of bumadizone calcium (Eumotol), a non-steroidal anti-inflammatory drug, has been carried out in 56 patients with rheumatoid arthritis. On both objective and subjective criteria bumadizone was superior to placebo and paracetamol at a statistically highly significant level (P less than 0,01). When tested against acetylsalicylic acid, bumadizone was more effective in 13 patients and less effective in 4 patients. Although this does not represent a statistically significant difference it does suggest that its anti-inflammatory and analgesic qualities are at least equal to those of salicylate in high dosages. There were no serious side-effects in  the patients who received bumadizone and the drug was better tolerated than either acetylsalicylic acid or paracetamol.
D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008314:Malonates / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos
D008314:Malonates; D010919:Placebos; D000082:Acetaminophen; D001241:Aspirin